Biotech Showcase™ 2015 biotechnology investor and partnering conference will take place January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco – Union Square. The event brings executive-level delegates representing top public and private investment firms with the goal to meet management teams of biotechnology and life science companies, including therapeutic companies, specialty pharma, platform and molecular diagnostic companies.
The conference kicks off on Monday, January 12 with a lunch plenary entitled “Value creation: Private and Public investment strategies and stage gates for success.” Moderator Mike Griffith, Executive VP Commercial Division of Ventiv Health, will engage panelists in a discussion on the key drivers that dictate “value” creation, and which pitfalls to avoid on the path to acquisition, partnership or joint commercialization models.
As each stakeholder places a different value on assets in each phase for different reasons, each type of investor will assess value with their own, unique focus. Most are aware that there is no longer one set of rules to evaluate pharma/biotech investments. But defining an investment strategy means examining existing company strategic strengths in established and existing areas of corporate investment. Whether a public or private investment, value still drives the deal.
Panelists include Stephen Bloch, General Partner of Canaan Partners; Ross Hammerman, Managing Director of UBS Investment Bank; John V. Oyler, Founder and CEO of BeiGene; and Melinda Richter, Head of Janssen Labs, Janssen Research & Development, LLC. Program and registration information for Biotech Showcase 2015 can be found online. Register before November 21, 2014 and save USD 200.